CAVERJECT IMPULSE Indication and Important Safety Information
Please scroll to see the Indication below.
Important Safety Information
CAVERJECT IMPULSE is indicated for the treatment of erectile dysfunction due to
neurogenic, vasculogenic, psychogenic, or mixed etiology.
The most common side effect of CAVERJECT IMPULSE was penile pain, reported by 37%
of patients in clinical studies. Only 3% discontinued CAVERJECT IMPULSE for this
reason.
CAVERJECT IMPULSE should not be used in men hypersensitive to alprostadil, men with
conditions that may predispose them to priapism, men with anatomical deformities
of the penis, men with penile implants, or men for whom sexual activity is not advisable
or is contraindicated. Penile fibrosis, including Peyronie's disease, was reported
in clinical trials with CAVERJECT IMPULSE.
Patients should be instructed to report any erection lasting 4 hours or longer.
Treatment of priapism should not be delayed more than 6 hours.
Each patient should be titrated to the lowest effective dose.
The product information in this site is intended only for residents of the United
States.
Indication
CAVERJECT® (CAVERJECT IMPULSE®, CAVERJECT Sterile Powder®, and CAVERJECT Injection®) is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
Intracavernosal CAVERJECT is also indicated as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
Please see full prescribing information.
CAVERJECT
IMPULSE® Dual Chamber System (alprostadil for injection)
Back to Top